In higher level organisms, inactivating mutations in Btk results in a condition known as X-linked agammaglobulinemia (XLA), characterised by the inability to produce mature B-cells and gamma globulins (including antibodies). The gene discussed is BTK; the disease is X-linked agammaglobulinemia.